Product image of Nimenrix (Tetanus Toxoid, N. Meningitidis Group C Polysaccharide, N. Meningitidis Group Y Polysaccharide, Neis) supplied by GNH India

Nimenrix

Active Ingredient:
Tetanus Toxoid, N. Meningitidis Group C Polysaccharide, N. Meningitidis Group Y Polysaccharide, Neis
Origin:
EU

Nimenrix (Tetanus Toxoid, N. Meningitidis Group C Polysaccharide, N. Meningitidis Group Y Polysaccharide, Neis)

Meningococcal conjugate vaccine, the active ingredient in Nimenrix, is a vaccine presented as a vaccine for intramuscular use. It prevents meningococcal disease caused by Neisseria meningitidis groups A, C, W‑135 and Y in individuals at risk, such as adolescents and travelers.

GNH India supplies Nimenrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pfizer Europe Ma Eeig

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nimenrix is a conjugate vaccine that targets invasive meningococcal disease caused by specific bacterial capsular groups.

  • Meningococcal disease (groups A, C, W‑135, Y): Provides active immunity to prevent invasive infection.
  • Adolescents and young adults: Reduces risk of outbreaks in high‑density settings such as schools and universities.
  • Travelers to endemic regions: Offers protection before travel to areas with known meningococcal circulation.

How It Works

  • Nimenrix contains capsular polysaccharides from Neisseria meningitidis groups A, C, W‑135 and Y covalently linked to tetanus toxoid. The conjugate formulation enables uptake by antigen‑presenting cells, leading to T‑cell dependent B‑cell activation and production of high‑affinity, long‑lasting antibodies that neutralize the bacterial capsular antigens and prevent colonisation and invasive disease.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: transient low‑grade temperature rise.
  • Headache: mild to moderate headache within 24‑48 hours.
  • Fatigue: temporary tiredness after vaccination.
  • Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder with ascending weakness.
  • Seizures: uncommon convulsive episodes post‑vaccination.
  • Severe hypotension: marked drop in blood pressure.
  • Persistent high fever: fever > 40 °C lasting more than 24 hours.
  • Acute allergic reaction: urticaria, angioedema, or bronchospasm.

Precautions & Warnings

Before administering Nimenrix, consider the following precautions:

  • Severe allergy: Do not vaccinate individuals with known hypersensitivity to any vaccine component.
  • Acute illness: Postpone vaccination in persons with moderate or severe febrile illness until recovery.
  • Age‑specific dosing: Follow recommended schedule for each age group as per prescribing information.
  • Immunocompromised patients: Monitor antibody response; vaccine may be less effective.
  • Fever monitoring: Observe infants and young children for post‑vaccination fever.
  • Store at 2‑8 °C: Keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccination with Nimenrix may be influenced by other medical products.

Major Interactions (Avoid)

  • Concurrent blood product administration: May diminish immune response to the vaccine.
  • Live attenuated vaccines given within 4 weeks: Potential interference with immune priming.

Moderate Interactions (Monitor Closely)

  • Immunosuppressive therapy: May reduce antibody generation; assess serologic response.
  • Antipyretics (e.g., acetaminophen) taken prophylactically: Could mask fever, a sign of reaction.
  • Pregnancy: Use with caution; monitor maternal and fetal health.
  • Antibiotics: Generally safe, but monitor for any unusual reactions.

Frequently Asked Questions

Nimenrix is a conjugate vaccine indicated for the prevention of invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W‑135 and Y. It is administered to individuals at risk, including adolescents, young adults, and travelers to endemic regions.

The vaccine contains capsular polysaccharides from the four meningococcal groups chemically linked to tetanus toxoid. This conjugation enables a T‑cell dependent immune response, leading to the production of high‑affinity antibodies that neutralise the bacterial capsule and provide long‑lasting protection.

The dosing schedule for Nimenrix is determined by the prescribing clinician based on age, health status and local immunisation guidelines. The prescriber decides the number of doses, intervals and any booster requirements.

Safety data for Nimenrix in pregnancy are limited, and the product is classified as pregnancy category unknown. Healthcare providers should weigh the benefits of protection against meningococcal disease against any potential risks. Breastfeeding is not a contraindication, but consult a physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Nimenrix is a quadrivalent conjugate vaccine covering groups A, C, W‑135 and Y, offering T‑cell dependent immunity and longer duration of protection compared with polysaccharide‑only formulations. Alternative vaccines may target fewer groups or use different carrier proteins, influencing immunogenicity and booster schedules.

Nimenrix must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Nimenrix is given by intramuscular injection, typically into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique.

Serious adverse events, although rare, include anaphylaxis, Guillain‑Barré syndrome, severe hypotension and seizures. Immediate medical attention is required if any signs of a severe allergic reaction or neurological symptoms develop after vaccination.

Individuals with a known severe allergy to any component of the vaccine, including tetanus toxoid, should not receive Nimenrix. Persons with a history of severe immediate hypersensitivity reactions to a previous dose of this vaccine should also be excluded.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetanus Toxoid, N. Meningitidis Group C Polysaccharide, N. Meningitidis Group Y Polysaccharide, Neis

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT